-
1.发明申请公开(公告)号：US20220389110A1
公开(公告)日：2022-12-08
申请号：US17662034
申请日：2022-05-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , Paul GAGNIER , David FELTQUATE
IPC: C07K16/28 , A61K39/395 , A61K31/404 , A61K45/06 , A61K31/506 , A61K31/44
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
-
2.发明申请公开(公告)号：US20170088626A1
公开(公告)日：2017-03-30
申请号：US15122827
申请日：2015-03-04
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , Paul GAGNIER , David FELTQUATE
IPC: C07K16/28 , A61K31/404 , A61K31/506 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2896 , A61K31/404 , A61K31/44 , A61K31/506 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2818 , A61K2300/00
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
-
公开(公告)号：US20180237534A1
公开(公告)日：2018-08-23
申请号：US15577375
申请日：2016-05-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Maria RODRIGUEZ , Xiang SHAO , Mohan SRINIVASAN , Brenda L. STEVENS , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Christine HUANG , Maria JURE-KUNKEL , Zheng YANG , Yan FENG , Patrick GUIRNALDA , Nils LONBERG , Bryan C. BARNHART , Aaron P. YAMNIUK , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL , Praveen AANUR , Mark J. SELBY
IPC: C07K16/28 , C07K16/30 , A61K39/395 , G01N33/574 , A61P35/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574 , G01N2333/70514
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
4.发明申请公开(公告)号：US20170247455A1
公开(公告)日：2017-08-31
申请号：US15505299
申请日：2015-08-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Maria JURE-KUNKEL , David M. Berman , Alan J. Korman , Mark J. Selby , Suba Krishnan
CPC classification number: C07K16/2818 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2878 , C07K16/3061 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to CD137.
-
公开(公告)号：US20160368998A1
公开(公告)日：2016-12-22
申请号：US15174268
申请日：2016-06-06
Applicant: Bristol-Myers Squibb Company
Inventor： Maria JURE-KUNKEL , Laura J. Hefta , Marc Santoro , Subinay Ganguly , Edward L. Halk
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K2039/505 , A61K2039/53 , A61K2039/55516 , C07K16/30 , C07K2317/21 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/75 , C07K2317/92 , C12N2740/15034 , A61K2300/00
Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
Abstract translation: 与人4-1BB结合并允许人4-1BB与人4-1BB配体结合的完全人抗体及其抗原结合部分。 一方面，抗体是IgG4抗体。 还提供了治疗受试者疾病的方法，包括向所述受试者施用治疗有效量的抗体。
-
Patent Agency Ranking
公开(公告)号：US20190184042A1
公开(公告)日：2019-06-20
申请号：US16305284
申请日：2017-05-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. MORIN , David DONNELLY , Dasa LIPOVSEK , Jochem GOKEMEIJER , Maria JURE-KUNKEL , David FABRIZIO , Martin C. WRIGHT , Douglas DISCHINO , Samuel J. BONACORSI, Jr. , Ralph Adam SMITH , Virginie LAFONT , Daniel COHEN , David K. LEUNG
CPC classification number: A61K51/088 , C07B59/00 , C07K16/2818
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US20190055320A1
公开(公告)日：2019-02-21
申请号：US16113061
申请日：2018-08-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC: C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
-
公开(公告)号：US20180127513A1
公开(公告)日：2018-05-10
申请号：US15520638
申请日：2015-11-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, JR. , Liang SCHWEIZER , Sandra V. HATCHER , Haichun HUANG , Pingping ZHANG
IPC: C07K16/40 , G01N33/574 , A61K39/395 , A61K45/06 , C07K16/28 , C07K16/30 , A61K47/68 , A61K39/00
CPC classification number: C07K16/40 , A61K39/39558 , A61K45/06 , A61K47/6871 , A61K2039/505 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , G01N33/57492 , G01N2333/916
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
-
公开(公告)号：US20240417471A1
公开(公告)日：2024-12-19
申请号：US18662447
申请日：2024-05-13
Applicant: Bristol-Myers Squibb Company
Inventor： John P. COGSWELL , Stacie M. GOLDBERG , Ashok K GUPTA , Maria JURE-KUNKEL , Xi-Tao WANG , Jon M. WIGGINTON
IPC: C07K16/28 , A61K39/00 , A61K39/395 , C07K16/18 , G01N33/574
Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US20190284293A1
公开(公告)日：2019-09-19
申请号：US16081115
申请日：2017-03-03
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, Jr. , Liang SCHWEIZER , Sandra V. HATCHER , Rachel A. ALTURA , Haichun HUANG , Pingping ZHANG , Edward J. HILT , Michael Nathan HEDRICK
Abstract: Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.036 seconds)
